VolitionRXVNRX
VNRX
About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Employees: 110
0
Funds holding %
of 6,812 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
115% more capital invested
Capital invested by funds: $4.89M [Q2] → $10.5M (+$5.64M) [Q3]
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
9.28% more ownership
Funds ownership: 9.75% [Q2] → 19.03% (+9.28%) [Q3]
19% less funds holding
Funds holding: 27 [Q2] → 22 (-5) [Q3]
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
721%
upside
Avg. target
$5
721%
upside
High target
$5
721%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 28% 1-year accuracy 43 / 155 met price target | 721%upside $5 | Buy Maintained | 10 Dec 2024 |
EF Hutton Jason Kolbert 28% 1-year accuracy 43 / 155 met price target | 721%upside $5 | Buy Maintained | 1 Nov 2024 |
Financial journalist opinion
Based on 3 articles about VNRX published over the past 30 days
Neutral
PRNewsWire
2 weeks ago
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
Volition to participate in the upcoming 14th Annual LifeSci Partners Corporate Access Event on January 15 th, 2025 at the Beacon Grand Hotel in San Francisco. HENDERSON, Nev.
Neutral
PRNewsWire
2 weeks ago
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
HENDERSON, Nev. , Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT (LDCT) scan, in patients suspected of lung cancer.
Neutral
PRNewsWire
3 weeks ago
VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev , Dec. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i) 445,648 shares of its common stock to certain directors and executive officers of the Company (the "Insiders") at an offering price of $0.5722 per share, and (ii) 2,857,389 shares of its common stock, together with common stock purchase warrants, composed of Form A warrants to purchase up to 2,857,389 shares of common stock and Form B warrants to purchase up to 1,428,693 shares of common stock (collectively, the "Warrants"), to other investors at a combined offering price of $0.5722 per share and accompanying warrants. The Form A warrants and Form B warrants have an exercise price per share of $0.5722 and $0.71525, respectively, are exercisable immediately, and expire five years from the issuance date.
Neutral
Seeking Alpha
1 month ago
VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript
VolitionRx Limited (NYSE:VNRX ) Q3 2024 Earnings Conference Call November 15, 2024 8:30 AM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Tom Butera - CEO, Volition Veterinary Diagnostic Development Andrew Retter - Chief Medical Officer Terig Hughes - CFO Cameron Reynolds - President & CEO Conference Call Participants Jason Kolbert - D. Boral Capital Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Investment Research Bruce Jackson - The Benchmark Company Operator Good day, ladies and gentlemen.
Neutral
PRNewsWire
1 month ago
VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
Neutral
PRNewsWire
1 month ago
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
Neutral
PRNewsWire
1 month ago
Volition Appoints Timothy I. Still as Chairman
HENDERSON, Nev. , Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024.
Neutral
PRNewsWire
1 month ago
Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating
HENDERSON, Nev. , Oct. 31, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report , from its 'NETs in sepsis management' symposium at ESICM Lives 2024 last month, which concluded that Nu.Q® NETs could be used to predict patients at greater risk of deteriorating from sepsis.
Neutral
PRNewsWire
2 months ago
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar
HENDERSON, Nev. , Oct. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new data, presented at ESICM LIVES 2024, the annual congress of the European Society of Intensive Care Medicine, earlier this week.
Neutral
PRNewsWire
2 months ago
Volition hosts NETs in sepsis management symposium at ESICM Lives 2024
HENDERSON, Nev. , Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu.Q® NETs to determine a 'treatable trait' to enhance sepsis management.
Charts implemented using Lightweight Charts™